Saturday 17 October 2026
Export ATEC’s income statement to Excel — free account
Alphatec Holdings, Inc.
ATEC Healthcare Medical Devices
Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 40.7%, free cash flow fell 146.9% and total debt fell 7.79%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.45
0.48
−4.39%
Follow ATEC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.02 | 4.13 | 2.13 | 1.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
156.79 | 152.66 | 1,298.28 | 66.03 | |
P/B ratio |
191.32 | 254.09 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.58 | 4.66 | 2.68 | 2.22 | |
EV/EBITDA |
821.61 | 155.25 | 43.67 | 29.31 | |
EV/Operating CF |
74.28 | 78.76 | 40.90 | 32.04 | |
EV/FCF |
(777.70) | (807.85) | (2,696.57) | (315.58) | |
Quick Ratio |
1.14 | 1.18 | 1.03 | 0.96 | |
Current Ratio |
1.99 | 2.06 | 1.90 | 1.89 | |
Net Debt/EBITDA |
36.23 | 18.36 | 79.25 | 14.28 | |
Debt/Assets |
71.09% | 63.37% | 63.53% | 64.57% | |
Debt/Equity |
48.64 | 40.35 | (94.99) | (42.32) | |
Asset Turnover |
0.95 | 0.98 | 0.99 | 1.03 | |
Operating CF/Net income |
(0.49) | (0.95) | (0.04) | (0.80) | |
Capex/Depreciation |
(0.40) | (0.55) | (0.53) | (0.75) | |
Interest Coverage |
(1.24) | (0.68) | (1.93) | (0.17) | |
Research and Development Expense of Revenue |
9.51% | 10.68% | 9.14% | 8.51% | |
Selling, General and Administrative Expense of Revenue |
63.26% | 60.44% | 71.34% | 62.76% | |
Intangible Assets out of Total Assets |
0.22 | 0.21 | 0.21 | 0.21 | |
Share Based Compensation of Revenue |
8.34% | 9.11% | 12.32% | 8.50% | |
Graham Net Nets |
(0.15) | (0.10) | (0.21) | (0.26) | |
Graham Number |
0.00 | 0.00 | 0.80 | 1.11 | |
Earnings Yield |
(7.15%) | (4.52%) | (7.54%) | (8.21%) | |
Free Cash Flow Yield |
(0.15%) | (0.14%) | (0.05%) | (0.42%) | |
Revenue per Share |
1.30 | 1.42 | 1.25 | 1.36 | |
Operating CF per Share |
0.09 | 0.14 | 0.01 | 0.13 | |
Capex per Share |
(0.07) | (0.10) | (0.09) | (0.14) | |
Free Cash Flow per Share |
0.02 | 0.04 | (0.08) | (0.01) | |
Cash per Share |
1.03 | 1.07 | 0.91 | 0.76 | |
Shareholders Equity per Share |
0.08 | 0.08 | (0.03) | (0.08) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.08 | 0.08 | (0.03) | (0.08) | |
Free Cash Flow |
3.15 | 5.72 | (13.02) | (1.58) | |
Working Capital |
218.95 | 231.70 | 215.92 | 211.05 | |
Capital Expenditures |
(10.89) | (14.96) | (14.31) | (22.09) | |
Net Current Asset Value |
(335.96) | (327.91) | (348.66) | (354.08) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.07 | 0.07 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
87.65 | 90.15 | 97.93 | 103.02 | |
Average Payables |
48.23 | 46.94 | 42.40 | 54.67 | |
Average Inventory |
175.00 | 172.35 | 178.45 | 182.32 | |
Average Assets |
766.57 | 783.46 | 792.48 | 790.66 | |
Average Common Equity |
5.07 | (0.87) | (45.64) | 5.85 |
Columns are period end dates